Select Publications
Journal articles
2010, 'The small GTPase Rab14 is required for osteoclast polarisation and bone resorption', Bone, 47, pp. S67 - S67, http://dx.doi.org/10.1016/j.bone.2010.04.129
,2009, 'The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo', Proceedings of the National Academy of Sciences of the United States of America, 106, pp. 16511 - 16516, http://dx.doi.org/10.1073/pnas.0902743106
,2009, 'Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro', British Journal of Pharmacology, 157, pp. 427 - 435, http://dx.doi.org/10.1111/j.1476-5381.2009.00160.x
,2009, 'The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts', Bone, 44, pp. 908 - 916, http://dx.doi.org/10.1016/j.bone.2009.01.010
,2009, 'RANKL increases the level of Mcl-1 in osteoclasts and reduces bisphosphonate-induced osteoclast apoptosis in vitro', Arthritis Research and Therapy, 11, http://dx.doi.org/10.1186/ar2681
,2009, 'Phosphonocarboxylates inhibit the second geranylgeranyl addition by Rab geranylgeranyl transferase', Journal of Biological Chemistry, 284, pp. 6861 - 6868, http://dx.doi.org/10.1074/jbc.M806952200
,2009, 'Peripheral blood monocytes are responsible for γδ T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP', British Journal of Haematology, 144, pp. 245 - 250, http://dx.doi.org/10.1111/j.1365-2141.2008.07435.x
,2009, 'Bone mineral affinity influences the distribution of a bisphosphonate and a lower affinity analogue in vivo', Bone, 44, pp. S430 - S431, http://dx.doi.org/10.1016/j.bone.2009.03.377
,2009, 'Fluvastatin does not prevent the acute-phase response to intravenous zoledronic acid in post-menopausal women', Bone, 44, pp. S236 - S237, http://dx.doi.org/10.1016/j.bone.2009.03.093
,2009, 'Functional analysis of mutations in rank that result in diseases with opposite phenotypes', Bone, 44, pp. S325 - S325, http://dx.doi.org/10.1016/j.bone.2009.03.617
,2009, 'GPR55: A novel cannabinoid receptor involved in the regulation of osteoclast function and bone mass', Bone, 44, pp. S138 - S138, http://dx.doi.org/10.1016/j.bone.2009.01.305
,2009, 'Synergistic effect of apomine and lovastatin on osteosarcoma cell growth', Bone, 44, pp. S273 - S273, http://dx.doi.org/10.1016/j.bone.2009.03.479
,2009, 'The differential distribution in vivo of fluorescently-labeled bisphosphonate analogues with different mineral affinity to bone surfaces', Bone, 44, pp. S57 - S57, http://dx.doi.org/10.1016/j.bone.2009.01.016
,2008, 'Fluorescently labeled risedronate and related analogues: "Magic linker" synthesis', Bioconjugate Chemistry, 19, pp. 2308 - 2310, http://dx.doi.org/10.1021/bc800369c
,2008, 'Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo', Cancer Research, 68, pp. 8945 - 8953, http://dx.doi.org/10.1158/0008-5472.CAN-08-2195
,2008, 'Human Osteoclast-Poor Osteopetrosis with Hypogammaglobulinemia due to TNFRSF11A (RANK) Mutations', American Journal of Human Genetics, 83, pp. 64 - 76, http://dx.doi.org/10.1016/j.ajhg.2008.06.015
,2008, 'Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations', AMERICAN JOURNAL OF HUMAN GENETICS, 83, pp. 64 - 76, http://dx.doi.org/10.1016/j.ajhg.2008.06.015
,2008, 'Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells', JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 12, pp. 928 - 941, http://dx.doi.org/10.1111/j.1582-4934.2008.00141.x
,2008, 'Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy', Osteoporosis International, 19, pp. 733 - 759, http://dx.doi.org/10.1007/s00198-007-0540-8
,2008, 'Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells', Bone, 42, pp. 848 - 860, http://dx.doi.org/10.1016/j.bone.2007.12.225
,2008, 'Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: Time-dependent inhibition of human farnesyl pyrophosphate synthase', Journal of Medicinal Chemistry, 51, pp. 2187 - 2195, http://dx.doi.org/10.1021/jm7015733
,2008, 'CMT3 alters mitochondrial function in murine osteoclast lineage cells', Biochemical and Biophysical Research Communications, 365, pp. 840 - 845, http://dx.doi.org/10.1016/j.bbrc.2007.11.054
,2008, 'Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells', Journal of Cellular and Molecular Medicine, 12, pp. 928 - 941, http://dx.doi.org/10.1111/j.1582-4934.2008.00141.x
,2008, 'Characterisation of the inhibition of rab prenylation by phosphonocarboxylates', Bone, 42, pp. S88 - S89, http://dx.doi.org/10.1016/j.bone.2007.12.167
,2008, 'Differential inhibition of rab geranylgeranyl transferase by stereoisomers of phosphonocarboxylates', Bone, 42, pp. S87 - S87, http://dx.doi.org/10.1016/j.bone.2007.12.164
,2008, 'Fluorescently labeled risedronate and related analogs: Design and evaluation as imaging probes', Bone, 42, pp. S36 - S36, http://dx.doi.org/10.1016/j.bone.2007.12.054
,2008, 'Nitrogen-containing bisphosphonates induce IPP/DMAPP accumulation selectively in peripheral blood monocytes due to efficient drug uptake', Bone, 42, pp. S84 - S85, http://dx.doi.org/10.1016/j.bone.2007.12.159
,2008, 'Structure activity relationships of nitrogen containing bisphosphonates which induce conformational changes in farnesyl pyrophosphate synthase', Bone, 42, pp. S71 - S71, http://dx.doi.org/10.1016/j.bone.2007.12.129
,2008, 'Structure activity relationships of phosphonocarboxylate inhibitors of rab geranylgeranyl transferase', Bone, 42, pp. S86 - S87, http://dx.doi.org/10.1016/j.bone.2007.12.163
,2008, 'Use of a fluorescent analogue of risedronate to study localisation and cellular uptake of bisphosphonates in vivo', Bone, 42, pp. S85 - S85, http://dx.doi.org/10.1016/j.bone.2007.12.160
,2008, 'Zoledronic Acid-Induced IPP/ApppI Formation In Vivo and In Vitro', Bone, 42, pp. S38 - S39, http://dx.doi.org/10.1016/j.bone.2007.12.060
,2007, 'Actin polymerization modulates CD44 surface expression, MMP-9 activation, and osteoclast function', Journal of Cellular Physiology, 213, pp. 710 - 720, http://dx.doi.org/10.1002/jcp.21137
,2007, 'The matricellular protein CYR61 inhibits osteoclastogenesis by a mechanism independent of α
2007, 'A comparison between the effects of hydrophobic and hydrophilic statins on osteoclast function in vitro and ovariectomy-induced bone loss in vivo', Calcified Tissue International, 81, pp. 403 - 413, http://dx.doi.org/10.1007/s00223-007-9078-1
,2007, 'The molecular mechanisms of action of bisphosphonates', Clinical Reviews in Bone and Mineral Metabolism, 5, pp. 130 - 144, http://dx.doi.org/10.1007/s12018-007-9004-0
,2007, 'Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL', Nature Genetics, 39, pp. 960 - 962, http://dx.doi.org/10.1038/ng2076
,2007, 'Apomine enhances the antitumor effects of lovastatin on myeloma cells by down-regulating 3-hydroxy-3-methylglutaryl-coenzyme A reductase', Journal of Pharmacology and Experimental Therapeutics, 322, pp. 228 - 235, http://dx.doi.org/10.1124/jpet.106.116467
,2007, 'Involvement of PLEKHM1 in osteoclastic vesicular transport and osteopetrosis in incisors absent rats and humans', Journal of Clinical Investigation, 117, pp. 919 - 930, http://dx.doi.org/10.1172/JCI30328
,2007, 'Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells', Molecular Cancer, 6, http://dx.doi.org/10.1186/1476-4598-6-18
,2007, 'A novel method for efficient generation of transfected human osteoclasts', Calcified Tissue International, 80, pp. 132 - 136, http://dx.doi.org/10.1007/s00223-006-0245-6
,2006, 'Molecular mechanisms of action of bisphosphonates: Current status', Clinical Cancer Research, 12, http://dx.doi.org/10.1158/1078-0432.CCR-06-0843
,2006, 'Recent advances in understanding the mechanism of action of bisphosphonates', Current Opinion in Pharmacology, 6, pp. 307 - 312, http://dx.doi.org/10.1016/j.coph.2006.03.005
,2006, 'The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs', Proceedings of the National Academy of Sciences of the United States of America, 103, pp. 7829 - 7834, http://dx.doi.org/10.1073/pnas.0601643103
,2006, 'Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis', Molecular Pharmacology, 69, pp. 1624 - 1632, http://dx.doi.org/10.1124/mol.105.020776
,2006, 'Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases', Journal of Bone and Mineral Research, 21, pp. 684 - 694, http://dx.doi.org/10.1359/jbmr.060118
,2006, 'Alkylamines cause Vγ9Vδ2 T-cell activation and proliferation by inhibiting the mevalonate pathway', Blood, 107, pp. 651 - 654, http://dx.doi.org/10.1182/blood-2005-03-1025
,2006, 'Alkylamines prevent osteoclast formation and activity by inhibiting the mevalonate pathway', Bone, 38, pp. 31 - 31, http://dx.doi.org/10.1016/j.bone.2006.01.124
,2006, 'Crystal structures and molecular interactions of risedronate and zoledronate with human farnesyl diphosphate synthase', Bone, 38, pp. 53 - 53, http://dx.doi.org/10.1016/j.bone.2005.12.050
,2006, 'Cytosolic entry of Bisphosphonates into macrophages and osteoclasts requires fluid-phase endocytosis and endosomal acidification', Bone, 38, pp. 47 - 47, http://dx.doi.org/10.1016/j.bone.2005.12.035
,2006, 'Inhibition of post-translational prenylation causes sustained activation of RAC, Cdc42 and Rho GTPases', Bone, 38, pp. 45 - 45, http://dx.doi.org/10.1016/j.bone.2005.12.031
,